Sensitivity
97.1 percent
- EndpointSubdural hemorrhage detection
- Population560 independent non-contrast head CT scans; 174 positive and 386 negative
- Tested versionJLK-SDH submitted in K243611; build not stated
FDA-cleared profile
JLK, Inc. · CT/CTA · FDA-cleared (510(k))
Authorized purpose: JLK-SDH analyzes non-contrast head CT for suspected hemispheric subdural hemorrhage and sends notification to a clinician for review in parallel to standard care; PACS/mobile previews may be compressed and are non-diagnostic, while full patient evaluation and uncompressed diagnostic viewing remain required.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: JLK-SDH analyzes non-contrast head CT for suspected hemispheric subdural hemorrhage and sends notification to a clinician for review in parallel to standard care; PACS/mobile previews may be compressed and are non-diagnostic, while full patient evaluation and uncompressed diagnostic viewing remain required.
Evidence takeaway. Evidence from the reviewed source record: Independent test used 560 non-contrast head CT scans, including 174 subdural hemorrhage-positive and 386 negative cases; training used 29,524 scans from U.S., Brazilian, and Korean institutions.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
97.1 percent
97.4 percent
0.974 AUC
K243611
The FDA describes the test set as independent of training data and includes 174 SDH-positive and 386 negative cases; independence of investigators or sponsorship was not established.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Non-contrast head CT in DICOM format; the reviewed labeling does not state a narrower scanner, slice-thickness, or reconstruction requirement.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-06 · FDA 510(k) K243611: JLK-SDH
Source context, not route validation: The FDA submission describes DICOM-compliant processing, PACS preview, mobile notification, and a JLK-hosted algorithm service; local interfaces and routing require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-06 · FDA 510(k) K243611: JLK-SDH
Source context, not route validation: The exact FDA package describes the JLK-SDH algorithm hosted on JLK servers that receive head CT images forwarded from CT scanners, plus a mobile software module for receiving and toggling notifications. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "This algorithm, hosted on JLK servers, is designed to analyze non-contrast CT images of the head acquired on CT scanners and forwarded to JLK servers." … "The mobile software module that enables user to receive and toggle notifications for suspected subdural hemorrhages". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 · FDA 510(k) K243611: JLK-SDH
Source context, not route validation: A notification that suspected subdural hemorrhage has been identified and should be reviewed; previews may be compressed through PACS and mobile applications, while diagnostic review uses non-compressed images.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-06 · FDA 510(k) K243611: JLK-SDH
Unresolved route: A notification that suspected subdural hemorrhage has been identified and should be reviewed; previews may be compressed through PACS and mobile applications, while diagnostic review uses non-compressed images.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-06 · FDA 510(k) K243611: JLK-SDH
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Packet wording: "This algorithm, hosted on JLK servers, is designed to analyze non-contrast CT images of the head acquired on CT scanners and forwarded to JLK servers." … "The mobile software module that enables user to receive and toggle notifications for suspected subdural hemorrhages". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Vendor statement, not an attestation; exact-release scope is not established.
The exact submission describes a JLK-hosted DICOM service that can send notifications and provide compressed previews through PACS and mobile applications while directing clinicians to uncompressed diagnostic review.
exact submission · checked 2026-09-06JLK's official MEDIHUB Stroke page describes a family platform spanning CT, CTA, MRI, and MRA algorithms, including JLK-ICH and JLK-LVO; current JLK-SDH packaging and local integration require confirmation.
product family · checked 2026-09-07Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public amount, range, currency, geography, or contract term was established.
Bounded web search on 2026-10-26 (query: "JLK ICH SDH reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Current onboarding, competency, and support commitments were not established.
Local acceptance testing, production monitoring, update control, and drift review were not established.
8 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics, evidenceStudies
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: productFamilyWorkflow, implementationCapabilities
Scope: security
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Infervision Medical Technology Co., Ltd.
Authorized purpose: Triage and prioritize suspected intracranial hemorrhage on non-enhanced head CT alongside standard-of-care interpretation.
Viz.ai, Inc.
Authorized purpose: Triage and notification of suspected head aneurysms during routine care; not a diagnostic device.
Circle Neurovascular Imaging, Inc
Authorized purpose: Triage and notify clinicians of suspected large-vessel occlusion on head CTA images.
Ge Medical Systems, LLC
Authorized purpose: Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history